• HOME
  • R&D
  • MP010 (TME-DP)

Development of treatment
for patients

MP010 (TME-DP)

MP010 (TME-DP)

Novel Strategy to Reshape an Immunosuppressive TME Barrier Innovative Mechanism with Novel Combination of targets

Tumor Microenvironment (TME)

  • Tumors create an immunosuppressive TME that blocks immune activation and builds ECM wall.
  • Fibroblasts and MSCs alter their shape and behavior, secreting higher levels of growth factors, cytokines, and chemokines.
  • As a result, the tumor stroma creates a supportive environment that promotes cancer progression and metastasis1)
  • EDB-FN, a protein modulates extracellular matrix stiffness, hindering targeted delivery to the tumor.
  • TGF-β plays a crucial role in the regulation of the tumor microenvironment, promoting cancer proliferation and progression.

MP010 : Bi-functional fusion protein, targeted trap

  • MP010 is a bifunctional agent designed to target specifically TME and preferentially trap TGF-β boosting immune response in TME.
  • The diverse biologic constructs were evaluated for optimal design and the most favorable construct was selected for development.

First-in-Class Bifunctional TME-Targeted Trap

Effectively binds and inhibits both targets with high tumor-specific affinity.

Reduces toxicity caused by systemic circulation by specifically targeting tumor-specific protein.

Induces infiltration of CD8+ and NK cells into tumor.

Designed to minimize off-target toxicity, as confirmed by RNAseq showing TME-specific gene modulation and a favorable safety profile with limited systemic immune impact.

Superior Efficacy in the Various Tumor Model

Pancreatic (PANC02, PKCY for KRASm), Breast (4T1 as TNBC), Colorectal (CT26 as cold tumor)


Strong T-Cell memory for Long-term anti-tumor effect

Upon tumor rechallenge, no growth of tumor was observed.

Presentations & Publications

Total 0

  • Mar, 2025

    Tm4sf19 inhibition ameliorates inflammation and bone destruction in collagen-induced arthritis by suppressing TLR4-mediated inflammatory signaling and abnormal osteoclast activation

    Bone Research
    Download

  • Nov, 2024

    MIMERET, a Novel Mitochondrial-Targeted Drug, Improves Hepatic Steatosis by Stimulating Mitochondrial Fatty Acid Beta-Oxidation to Prevent Lipid Accumulation

    AASLD 2024
    Download

  • Nov, 2024

    Vactosertib, a TGF-β signaling inhibitor, in combination with Durvalumab increased mOS in ≥2L treatment of patients with PD-L1-positive advanced NSCLC

    SITC 2024
    Download

  • Aug, 2024

    The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial

    Nature Communications
    Download

  • Jul, 2024

    Oral transforming growth factor-beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity

    Cancer Communications
    Download

  • Nov, 2023

    Tm4sf19 deficiency inhibits osteoclast multinucleation and prevents bone loss

    Metabolism 151
    Download

  • Apr, 2023

    Vactosertib combined treatment with T1-44, a PRMT5 activity inhibitor, improves the survival and inhibits tumor invasion of murine pancreatic cancer model

    American Association for Cancer Research 2023(AACR 2023)
    Download

  • Feb, 2023

    Combination treatment of T1-44, a PRMT5 inhibitor with Vactosertib, an inhibitor of TGF-β signaling, inhibits invasion and prolongs survival in a mouse model of pancreatic tumors

    Cell Death and Disease (2023)
    Download

  • Jan, 2023

    Discovery of TRD-93 as a novel DRAK2 inhibitor

    BULLETIN OF THE KOREAN CHEMICAL SOCIETY
    Download

  • Dec, 2022

    MAST4 controls cell cycle in spermatogonial stem cells

    Cell proliferation(IF : 8.755)
    Download

  • Dec, 2022

    Therapeutic Implications of TGF-β Pathway in Desmoid Tumor Based on Comprehensive Molecular Profiling and Clinicopathological Properties

    Cancers
    Download

  • Oct, 2022

    ESRP1-regulated isoform switching of LRRFIP2 determines metastasis of gastric cancer

    Nature communication
    Download

  • Sep, 2022

    Phase 1b Study of Vactosertib in Combination with FOLFOX in Patients with Metastatic Pancreatic Ductal Adenocarcinoma who have Failed First-Line Gemcitabine/nab-Paclitaxel

    AACR Special Conference on Pancreatic Cancer 2022
    Download

  • Jan, 2022

    Phase 1b Study of Vactosertib in Combination with nal-IRI plus 5FU/LV in Patients with Metastatic Pancreatic Ductal Adenocarcinoma who Failed First-Line Gemcitabine/nab-Paclitaxel

    ASCO GI 2022
    Download

  • Nov, 2021

    Tumor Microenvironment based on PD-L1 and CD8 T-cell infiltration correlated with the survival of MSS mCRC patients treated vactosertib in combination with pembrolizumab

    SITC 2021
    Download

  • Nov, 2021

    Spatial analysis of tumor-infiltrating lymphocytes correlates with the response of metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab

    SITC 2021
    Download

  • Jun, 2021

    Efficacy and Safety of Vactosertib and Pembrolizumab Combination in Patients with Previously Treated Microsatellite Stable Metastatic Colorectal Cancer

    ASCO 2021
    Download

  • Jun, 2021

    Phase 1b trial of Vactosertib in Combination with Pomalidomide in Relapsed Multiple Myeloma: A Corticosteroid-Free Approach by Targeting TGF-β Signaling Pathway

    ASCO 2021
    Download

  • Apr, 2021

    BAG2 Promotes Tumorigenesis and Metastasis by Regulating the Cathepsin B Cleavage in Triple Negative Breast Cancer Cells

    AACR 2021
    Download

  • Apr, 2021

    DRAK1 suppresses inflammation induced cervical cancer progression by targeting TRAF6 protein

    AACR 2021
    Download

  • Apr, 2021

    Beneficial effect of vactosertib combined with nal IRI5 FULV in pancreatic cancer treatment

    AACR 2021
    Download

  • Apr, 2021

    Genomic and transcriptomic analyses of desmoid tumor reveals enrichment of transforming growth factor beta responsive signature

    AACR 2021
    Download

  • Nov, 2020

    Vactosertib and Durvalumab as Second or Later Line Treatment for PD-L1 Positive Non-small Cell Lung Cancer: Interim Result

    SITC 2020
    Download

  • Sep, 2020

    Safety and Efficacy of Vactosertib, a TGFBR1 Kinase Inhibitor, in Combination with Paclitaxel in Patients with Metastatic Gastric Adenocarcinoma

    ESMO Congress 2020
    Download

  • May, 2020

    A Phase 1 study of TGF-β inhibitor, Vactosertib, in combination with Imatinib in patients with advanced desmoid tumor (aggressive fibromatosis)

    ASCO 2020
    Download

  • Nov, 2019

    Safety and Preliminary clinical activity of Vactosertib, a selective TGF-β receptor I kinase inhibitor, in combination with Durvalumab in advanced Non-small cell lung cancer patients with low PD-L1 expression

    SITC 2019
    Download

  • Nov, 2019

    Safety and preliminary clinical activity of Vactosertib, a selective TGF-β receptor I kinase inhibitor, in combination with Pembrolizumab in patients with metastatic colorectal or gastric cancer

    SITC 2019
    Download

  • Nov, 2019

    TGF-β as a promising therapeutic target for treating Osteosarcoma

    Innovation in AYA cancer
    Download

  • Jun, 2018

    TGF-β Responsive signature is associated with anti-tumor effect of Vactosertib, a potent oral TGF-β receptor type1(TGFBRI) inhibitor in patients with advanced solid tumors

    ASCO 2018
    Download